Dr. Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapuetics since December 2017. He joined CRISPR in August 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer starting May 2017. Prior to joining our company, he was a Partner at McKinsey & Company, where he had a role in the Pharmaceutical and Medical products practice and co-led the biotech practice. He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics.
Documentaries, videos and podcasts
- CRISPR TherapeuticsA biopharmaceutical and gene editing company founded in 2013. CRISPR Therapeutics AG is based in Zug, Switzerland and CRISPR Therapeutics, Inc. is the U.S. subsidiary with R&D operations in Cambridge, Massachusetts and business offices in London, U.K.
- Chief executive officerHighest-ranking corporate officer or administrator
- CRISPRClustered regularly interspaced short palindromic repeats (CRISPR) is a prokaryotic adaptive immune response that provides immunity against foreign nucleic acids, such as viral DNA and bacterial plasmids, through the use of crRNAs (CRISPR RNAs) and associated Cas genes.